title: Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
abstract: There is evidence that patients with moderate to severe psoriasis have an increased risk of conditions such as cardiovascular disease, obesity, diabetes mellitus, and metabolic syndrome. The precise mechanisms underlying the observed increase in cardiovascular disease in psoriasis remain to be defined but inflammatory pathways mutual to both conditions are probably involved. Suppression of systemic inflammation in psoriasis could help reduce cardiovascular inflammation but robust evidence is still lacking evidence is lacking. This article summarizes the current literature on cardiovascular and metabolic comorbidities in psoriasis, identifies research gaps, and suggests management strategies to reduce cardiovascular risk in patients with moderate to severe psoriasis.
authors.affiliation: Department of Dermatology, Baylor University Medical Center Dallas, 3900 Junius Street, Suite 145, Dallas, TX 75246, USA. Electronic address: caitrionaryan80@gmail.com.
authors.forename: Caitriona
authors.initials: C
authors.lastname: Ryan
authors.affiliation: St Vincent's University Hospital, University College Dublin, Elm Park, Dublin 4, Ireland.
authors.forename: Brian
authors.initials: B
authors.lastname: Kirby
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D054392:Adipokines / Q000378:metabolism*; D000437:Alcoholism / Q000453:epidemiology; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D015897:Comorbidity; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000453:epidemiology; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications* / Q000453:epidemiology* / Q000378:metabolism; D024821:Metabolic Syndrome / Q000453:epidemiology; D008727:Methotrexate / Q000627:therapeutic use; D009765:Obesity / Q000453:epidemiology; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology*; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab
chemical_list: D054392:Adipokines; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D005650:Fumarates; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069549:Ustekinumab; D017255:Acitretin; D008727:Methotrexate
keywords: Cardiovascular; Comorbidities; Diabetes; Metabolic syndrome; Myocardial infarction; Obesity; Psoriasis; Smoking